Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Return on Equity (2016 - 2025)

Altimmune (ALT) has disclosed Return on Equity for 15 consecutive years, with 0.48% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity rose 24.0% to 0.48% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.48%, a 24.0% increase, with the full-year FY2024 number at 0.6%, down 13.0% from a year prior.
  • Return on Equity was 0.48% for Q3 2025 at Altimmune, up from 0.58% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.04% in Q1 2021 to a low of 0.74% in Q4 2024.
  • A 5-year average of 0.45% and a median of 0.48% in 2025 define the central range for Return on Equity.
  • Biggest YoY gain for Return on Equity was 52bps in 2021; the steepest drop was -39bps in 2021.
  • Altimmune's Return on Equity stood at 0.38% in 2021, then decreased by -13bps to 0.44% in 2022, then fell by -18bps to 0.51% in 2023, then crashed by -44bps to 0.74% in 2024, then skyrocketed by 35bps to 0.48% in 2025.
  • Per Business Quant, the three most recent readings for ALT's Return on Equity are 0.48% (Q3 2025), 0.58% (Q2 2025), and 0.68% (Q1 2025).